Drug Profile
Dapagliflozin/metformin/saxagliptin - AstraZeneca
Alternative Names: Dapagliflozin/metformin extended release/saxagliptin; Dapagliflozin/saxagliptin/metformin extended release; Dapaglifozin/metformin hydrochloride/saxagliptin - AstraZeneca; Metformin extended release/dapagliflozin/saxagliptin; Metformin extended release/saxagliptin/dapagliflozin; Metformin hydrochloride, saxagliptin and dapagliflozin - AstraZeneca; Qternmet XR; Qtrilmet; Saxagliptin/metformin extended release/dapagliflozinLatest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Benzhydryl compounds; Biguanides; Chlorobenzenes; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Type 2 diabetes mellitus
Most Recent Events
- 25 Apr 2022 Discontinued - Phase-III for Type 2 diabetes mellitus in Canada (PO) (AstraZeneca pipeline, April 2022)
- 25 Apr 2022 Discontinued - Phase-III for Type 2 diabetes mellitus in Mexico (PO) (AstraZeneca pipeline, April 2022)
- 25 Apr 2022 Discontinued - Phase-III for Type 2 diabetes mellitus in Russia (PO) (AstraZeneca pipeline, April 2022)